Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Safety planning Clear all
Enrolling by invitation Not applicable Interventional

SAFETY-Parent: Online Learning Module to Support Parents of Suicidal Youth

NCT06460220
View directory record Official record
Conditions
Suicide, Suicide, Attempted, Suicide and Self-harm, Suicide Threat
Interventions
Safe Alternatives for Teens and Youth - Parent (SAFETY-P), Treatment As Usual (TAU)
Behavioral
Lead sponsor
Jennifer Hughes
Other
Eligibility
10 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 23, 2026, 8:18 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Pilot Testing Suicide Risk Prediction Algorithms in Primary Care

NCT07068685
View directory record Official record
Conditions
Suicide Prevention, Suicide Risk | Patient
Interventions
Suicide risk prediction algorithm
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 23, 2026, 8:18 AM EDT
Recruiting Phase 1 Interventional

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

NCT05768932
View directory record Official record
Conditions
Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
Interventions
BAL0891, Tislelizumab, Paclitaxel
Drug · Combination Product
Lead sponsor
SillaJen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Lethal Means Counseling and an Active Control Condition, With and Without Provision of Gun Locks

NCT03375099
View directory record Official record
Conditions
Intentional Self-Harm by Other Specified Means
Interventions
Lethal Means Counseling, Health and Stress Reduction
Behavioral
Lead sponsor
University of Southern Mississippi
Other
Eligibility
18 Years to 60 Years
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Sep 23, 2026, 8:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

NCT06483555
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
Interventions
Gemcitabine, Nab paclitaxel, Erlotinib, NALIRIFOX, Folfirinox
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

NCT03066830
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
28
States / cities
Litchfield Park, Arizona • Peoria, Arizona • Greenbrae, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

NCT00402181
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Dexamethasone
Biological · Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Duarte, California • Norwalk, Connecticut • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting

NCT04309500
View directory record Official record
Conditions
Mild Cognitive Impairment, Healthy Aging
Interventions
Personalized DAT Risk Disclosure Protocol
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 23, 2026, 8:18 AM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

NCT04032158
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 23, 2026, 8:18 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)

NCT00951743
View directory record Official record
Conditions
HIV Infections
Interventions
Adaptavir (monomeric DAPTA)
Drug
Lead sponsor
Rapid Laboratories Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2009 · Synced Sep 23, 2026, 8:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)

NCT02460874
View directory record Official record
Conditions
Cerebral Edema, Brain Metastases
Interventions
Glyburide, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Women and Child, Safety, Health, and Empowerment

NCT05940129
View directory record Official record
Conditions
Gender-based Violence
Interventions
Women and Child, Safety, Health and Empowerment (WC-SHE)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 23, 2026, 8:18 AM EDT
Withdrawn Phase 1 Interventional

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

NCT07073183
View directory record Official record
Conditions
Squamous NSCLC
Interventions
CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg
Biological
Lead sponsor
CureVac
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Fairfax, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Not applicable Interventional Results available

Establishing Efficacy of an Inpatient Intervention and Phone App to Reduce Suicidal Risk

NCT03825588
View directory record Official record
Conditions
Suicidal Ideation, Suicide, Attempted
Interventions
ASAP (As Safe As Possible), BRITE smart phone app, TAU (treatment as usual)
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 17 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 23, 2026, 8:18 AM EDT
Recruiting Phase 3 Interventional

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

NCT05317858
View directory record Official record
Conditions
Brain Tumor, Non Small Cell Lung Cancer
Interventions
Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab, Cemiplimab, Nivolumab, Iptilimumab
Device · Drug
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Phoenix, Arizona • Newport Beach, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Not applicable Interventional Results available

Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)

NCT01600482
View directory record Official record
Conditions
Cardiac Disease, Coronary Artery Disease
Interventions
CELT ACD
Device
Lead sponsor
Vasorum Ltd
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Camden, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Sep 23, 2026, 8:18 AM EDT
Recruiting Phase 1 Interventional

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

NCT06613100
View directory record Official record
Conditions
Prostate Cancer
Interventions
Xaluritamig, GnRH Antagonist
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
7
States / cities
San Francisco, California • St Louis, Missouri • Columbus, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly

NCT02914171
View directory record Official record
Conditions
Ebstein Anomaly
Interventions
Autologous Bone Marrow-derived Mononuclear Cells, Insertable cardiac monitor
Biological · Device
Lead sponsor
Timothy J. Nelson
Other
Eligibility
6 Months to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 23, 2026, 8:18 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Optimizing a Technology-based Body and Mind Intervention

NCT05778604
View directory record Official record
Conditions
Fall, Fear of Falling, Physical Inactivity, Sedentary Behavior
Interventions
Physio-feedback, Cognitive reframing, Peer-led exercises, CDC older adults fall prevention
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
60 Years and older
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Not applicable Interventional Results available

Emergency Department Longitudinal Integrated Care

NCT03699085
View directory record Official record
Conditions
Opioid-use Disorder, Emergency Department
Interventions
ED-LINC
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 23, 2026, 8:18 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Virtual Reality Lethal Means Safety Training

NCT07219355
View directory record Official record
Conditions
Suicide, Attempted, Suicide, Completed, Suicide Prevention, Mental Health Training, Rural Health, Veterans
Interventions
Virtual Reality Lethal Means Safety Training, 2D Video Training
Behavioral
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 23, 2026, 8:18 AM EDT
Not listed Not applicable Interventional

Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Intermediate Risk Prostate Cancer

NCT04656678
View directory record Official record
Conditions
Prostate Cancer, Prostate Disease
Interventions
Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance
Device
Lead sponsor
Northwell Health
Other
Eligibility
45 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Lake Success, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

NCT03479892
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0194-0499, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 23, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

NCT03972306
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Ocrelizumab, rHuPH20
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
18
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 23, 2026, 8:18 AM EDT